Outlook Therapeutics, Inc. (then Oncobiologics, Inc.) — Form 10-Q Summary
Business context and reporting period
The filing is for the fiscal first quarter ended December 31, 2017, with comparative results for the three months ended December 31, 2016. The company was a clinical-stage biosimilar developer with no products approved for sale. Its lead candidates, ONS-3010 (adalimumab biosimilar) and ONS-1045 (bevacizumab biosimilar), had completed Phase 1; advancement toward Phase 3 was contingent on securing development partners. Reported revenue came from collaboration and licensing agreements.
Financial performance and position
| Metric | Quarter ended Dec. 31, 2017 | Quarter ended Dec. 31, 2016 |
|---|---|---|
| Collaboration revenue | $0.772 million | $0.303 million |
| Research and development expense | $0.402 million | $13.228 million |
| General and administrative expense | $3.549 million | $4.871 million |
| Operating loss | $3.180 million | $17.795 million |
| Net loss | $1.921 million | $19.098 million |
| Net loss attributable to common stockholders | $17.726 million | $19.098 million |
| Basic and diluted loss per share | $0.71 | $0.82 |
| Net cash used in operations | $8.671 million | $5.842 million |
- Revenue was entirely from collaborations; the filing reports no product sales. Profit margins are not meaningful given the company’s development-stage operations and losses.
- The gap between 2017 net loss and loss attributable to common stockholders reflects a $15.355 million beneficial-conversion charge on Series A preferred stock and $0.451 million of Series A dividends.
- Cash was $13.838 million at December 31, 2017, versus $3.186 million at September 30, 2017. Total assets were $32.277 million; total liabilities were $40.175 million. Stockholders’ deficit was $25.088 million.
- Current liabilities were $31.201 million. Senior secured notes had $13.5 million principal due in December 2018 (carrying value $12.192 million after discount); $4.613 million of stockholder notes were payable on demand.
- Cash used in investing was $1.075 million; financing provided $20.398 million. The financing inflow primarily reflected the October Series A preferred-stock placement.
- The filing does not provide a meaningful operating margin or a clear standalone gross-margin figure.
Material changes versus the prior comparable period
- Collaboration revenue rose by $0.469 million, largely from recognition of deferred revenue under the GMS Tenshi arrangement.
- R&D expense fell by $12.825 million. Management attributed the decline to postponing planned Phase 3 trials pending partners, lower development and compensation costs, cost reductions, and a $3.229 million favorable settlement of a clinical-development contract.
- G&A expense fell by $1.321 million, primarily due to cost-reduction efforts.
- Operating loss narrowed substantially, but operating cash use increased by $2.829 million, primarily reflecting payments of prior-period payables and accrued expenses and certain R&D prepayments.
- The quarter included a $1.252 million loss on extinguishment of debt from exchanging $1.5 million of senior notes and accrued interest for Series B preferred stock. A $3.151 million tax benefit arose from selling New Jersey tax attributes.
Outlook, risks, and unusual items
- Management expected December 31 cash to fund operations only through June 2018 and stated that substantial additional financing was required. Failure to secure financing or licensing/co-development agreements could force the company to scale back plans or place activities on hold.
- The filing states that recurring losses, negative operating cash flows, senior debt, and demand-payable stockholder notes raise substantial doubt about the company’s ability to continue as a going concern. The interim statements contain no adjustments for the possible outcome of that uncertainty.
- Management was pursuing financing through equity or debt, partnerships and licensing, and contract development and manufacturing services. There is no assurance these efforts would succeed.
- Key business risks include clinical and regulatory uncertainty, development costs and timing, competition, and the need for partner support and future market acceptance. The company anticipated higher R&D spending as programs progressed, but Phase 3 advancement depended on obtaining partners.
- Series A preferred stock accrued dividends at 10% annually, compounded quarterly. It was initially convertible into approximately 37.8 million common shares; related warrants covered 16.75 million shares at a $0.90 exercise price. Total common-stock warrants outstanding were approximately 28.1 million, creating significant potential dilution.
- A February 2018 lease amendment committed the company to a ten-year lease arrangement, with stated future minimum rental payments totaling $5.482 million.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It reported no material pending legal claims.
Important facts for investors to verify
- Whether the company secured financing or partnerships sufficient to extend the stated cash runway beyond June 2018.
- The terms, maturity, and repayment status of the $13.5 million senior notes and $4.6 million demand-payable stockholder notes.
- Whether ONS-3010 and ONS-1045 advanced toward Phase 3, and what partner funding or rights were obtained.
- The potential dilution from Series A and Series B conversion rights, warrants, and other equity awards.
- The sustainability of collaboration revenue and the effect of the one-time tax benefit and clinical-contract settlement on reported results and cash flows.